John Haurum

John is a non-executive Director in several European biotech companies, including AgomAb, Synklino, Synact, Storm and Neophore. Prior, he was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. From 2010 to 2012, he held the position of VP Research at ImClone Systems, New York, and from 2000 to 2009 he was the Chief Scientific Officer and Co-Founder of Symphogen, Denmark. After graduating with a degree in Medicine in Aarhus, Denmark in 1992, John received a DPhil in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England.